DNER and small cell lung carcinoma: Among all tested conditions, BET inhibitor GSK525762 (I-BET762) showed a significant additive effect with PARP inhibitor BMN-673 (Talazoparib) in four out of seven tested MYCs-amplified SCLC cell lines, Lu135, H2141, H446, and HCC33 (Figure 1C and Figure S1).